FDA Postpones Meeting to Review Over-the-Counter Birth Control Pills

October 26, 2022

(Axios) – The Food and Drug Administration on Wednesday indefinitely postponed a meeting of outside experts to help decide whether to allow over-the-counter sales of birth control pills.  Driving the news: HRA Pharma sought the designation last July for its Opill contraceptive. The scheduling of an advisory committee meeting for Nov. 18 was considered unusually fast for the agency. (Read More)